210 results about "Histocytochemistry" patented technology

Presented herein are systems, methods, and non-transient computer readable media for determining predicted response scores of subjects. A computing system may identify a first feature set for a first subject to be administered with immunotherapy to address a condition. The first feature set may include one or more of: (i) a first radiological feature identified in a tomogram of a section associated with the condition in the first subject, (ii) a first immunohistochemistry (IHC) feature derived from an image of a sample associated with the first subject, and (iii) a first genomic feature obtained from gene sequencing of the first subject for genes associated with the condition. The computing system may apply the first feature set to a model. The computing system may determine, from applying the first feature set to the model, a predicted score identifying a response to the immunotherapy to be administered to the first subject.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention discloses a tomato LACS2 gene promoter and application thereof, and belongs to the technical field of biology. On one hand, the invention provides the tomato LACS2 gene promoter, and on the other hand, the invention provides application of the tomato LACS2 gene promoter in promoting target gene expression in plants. According to the invention, a tomato LACS2 gene promoter fragment (788bp) is constructed to drive an EGFP-GUS (Enhanced Green Fluorescent Protein-Glucuronidase) gene fusion expression vector. GUS histochemical staining and laser confocal microscopy observation prove that the promoter fragment can guide normal expression of the reporter gene in the tomato epidermis. Therefore, the LACS2 promoter can be used for researching development, quality improvement and postharvest preservation of tomato peels and specific expression of exogenous genes in the tomato peels.

In alternative embodiments, provided are chimeric, synthetic or recombinant antibodies (Ab) against the human homologous box NKX-2. 1 (also known as NK2 homologous box 1, or thyroid transcription factor 1 (TTF-1)) protein, including articles of manufacture and kits comprising them, and methods of making and using them, including, for example, their use in the detection or diagnosis and treatment of cancer. In alternative embodiments, an anti-NKX-2. 1 (TTF-1) antibody provided herein is used with an agent for determining whether NKX-2. 1 (TTF-1) expression or activity is present, reduced or deleted; or the sensitivity of the specific binding of the Ab or the antigen (Ag) binding fragment or protein (ABP) or the monomer or dimer ABP provided by the invention with the squamous cell carcinoma cells is lower than the sensitivity of the specific binding with the adenocarcinoma cells (or binding with lower affinity), so that false positives of the squamous cell carcinoma are less, and the positive recognition of the lung adenocarcinoma is better.

The invention relates to the field of medical detection, and particularly provides a diagnostic model for predicting prognosis of gastric cancer CAR-T cellular immunotherapy and application of the diagnostic model. According to the present invention, the content and the spatial distribution map of the CLDN18.2 positive gastric cancer tissue sample microenvironment component are systematically analyzed by integrating the multiple fluorescence immunohistochemical detection and the full-slice digital imaging quantitative analysis method for the first time; through multi-dimensional evaluation of a tumor microenvironment under the treatment background of a targeted CLDN18.2 chimeric antigen receptor T cell immunotherapy CT041, a diagnosis model for predicting the prognosis of the gastric cancer CAR-T cell immunotherapy is established for the first time, accurate screening of benefited people and risk stratification before treatment are realized, treatment selection is guided, and the treatment effect is improved.

A deep learning-based digital / virtual staining method and system enables the creation of digitally / virtually-stained microscopic images from label or stain-free samples. In one embodiment, the method of generates digitally / virtually-stained microscope images of label-free or unstained samples using fluorescence lifetime (FLIM) image(s) of the sample(s) using a fluorescence microscope. In another embodiment, a digital / virtual autofocusing method is provided that uses machine learning to generate a microscope image with improved focus using a trained, deep neural network. In another embodiment, a trained deep neural network generates digitally / virtually stained microscopic images of a label-free or unstained sample obtained with a microscope having multiple different stains. The multiple stains in the output image or sub-regions thereof are substantially equivalent to the corresponding microscopic images or image sub-regions of the same sample that has been histochemically stained.

The invention provides an application of narirutin in preparation of a medicine for preventing and / or treating osteoclast of inflammatory arthritis, relates to the technical field of biomedicine, and adopts a collagen-induced mouse arthritis model to observe the treatment effect of the narirutin on the osteoclast of the inflammatory arthritis. The arthritis activity degree of the mouse is analyzed through general claw photographing, thickness measurement, near-infrared temperature measurement and a claw imprinting experiment, three-dimensional reconstruction and bone trabecula analysis are carried out on local joints and the whole body bone mass of the mouse through micro-CT scanning, and Hamp is applied; e, dyeing and Famp; through histological staining analysis such as O staining and TRAP staining, in combination with immunohistochemical staining and the like, the narirutin is proved to play a role in treating inflammatory arthritis, inhibit macrophage pro-inflammatory M1 type polarization, relieve the inflammation level, improve the bone mass of local joints and the whole body, and further improve bone destruction in inflammatory arthritis diseases. The narirutin provides a new way for medicine prevention and treatment of inflammatory arthritis.

The utility model relates to a staining kit, in particular to an immunohistochemical staining kit. The kit comprises a storage box, a clamping plate is arranged in the storage box, a plurality of clamping grooves are evenly formed in the clamping plate, a kit body is arranged in the clamping grooves, a plurality of placing grooves are evenly formed in the kit body around the circle center, reagent bags are arranged in the placing grooves, and different reagents are stored in the reagent bags; a sliding groove is formed in the inner wall of the top end of the kit close to the placing groove, and a cutting assembly is slidably connected into the sliding groove and used for cutting the reagent capsule. According to the kit storage box, a combined structure of the clamping grooves and the kits is designed, and the kits are placed in the clamping grooves, so that the kits are orderly arranged in the storage box and are convenient to manage and take, the efficiency of an experiment preparation stage is favorably improved, and disorder and loss of the kits are reduced; the reagent bag body can be stably placed in the placing groove, stability and safety of the reagent in the storage process are guaranteed, meanwhile, the reagent bag body can rapidly release the reagent into the kit after being cut through the arrangement of the liquid inlet, automatic feeding of the reagent is achieved, and complexity and errors of manual operation are avoided.

The method comprises the following steps: fixing with a pre-fixing solution, wrapping and forming with a solid agent, fixing with a fixing solution, embedding with an embedding agent, decomposing melanin with a melanin decomposing solution, pre-decoloring with a pre-decoloring solution, decoloring with a decoloring solution, and eluting with a rinsing solution. The invention provides a melanin removing method capable of effectively avoiding retina RPE layer cell exfoliation, protein denaturation and nucleic acid degradation. The method mainly comprises the following steps: keeping the original state of tissue cells by adopting a pre-fixing solution, keeping the complete tissue structure by adopting a solid agent, decomposing melanin particles by adopting a melanin decomposing solution composed of various extracts, separating melanin by adopting a pre-decoloring solution and a decoloring solution, eluting the melanin decomposed on the surface of the tissue by adopting a rinsing solution, and the like. On the premise that the retina tissue structure is intact and protein, nucleic acid and cell structures on the surface of the tissue section are not damaged, melanin particles in the tissue section are effectively decomposed, the biological activity of various organelles on the surface of the section is kept, and the requirements of subsequent chemical staining of various tissues are met.

The invention discloses an anti-soluble transferrin receptor monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibody detection. According to the antibody, an L101-F760 amino acid sequence of human TfR protein is used as an immunogen, specific screening of B cells, reverse RNA (Ribonucleic Acid) into cDNA (Complementary Deoxyribose Nucleic Acid) through RT-PCR (Reverse Transcription-Polymerase Chain Reaction), then homologous recombination is performed to construct heavy and light chain vectors, and finally multiple rounds of screening are performed to obtain the purified sTfR monoclonal antibody, so that the sTfR protein can be specifically recognized, and the antibody has the advantages of high specificity and high sensitivity and can be widely applied to the field of immunotherapy. The natural sTfR protein in human serum can be recognized. The kit is applied to the detection and screening fields of immunohistochemistry, immunofluorescence chemistry, western blot, co-immunoprecipitation, indirect ELISA, flow cytometry and the like, especially has low background and no interference of non-specific binding impure protein during immunohistochemistry detection, can obtain more accurate detection and evaluation results, avoids interference of false positive and false negative, and has high detection accuracy. The method has great application value in the aspects of basic scientific research and clinical pathology detection.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

Techniques for using combination stain types for machine learning models for digital pathology are described herein. In an example, a system accesses a first image of a sample comprising an immunohistochemistry (IHC) stain for a biomarker. The system accesses a second image of the sample comprising a hematoxylin and eosin (H&E) stain for nuclei. The system can segment tissue regions in the one or more first images and the second image, partitions the tissue regions in the one or more first images and the second image, and extracts features from the set of tiles using a feature extractor. The system can generate, by a machine-learning model, an output classification indicating a first phenotype based on the features extracted from the set of tiles. The machine-learning model can include one or more classifiers and an aggregation model that provides an aggregated output for the set of tiles.

A system and method for performing virtual birefringence imaging and virtual staining (e.g., Congo red) of label-free human tissue is disclosed to show that a single trained neural network can rapidly transform autofluorescence images of label-free tissue into brightfield and polarized microscopy images, matching their histochemically-stained versions. Blind testing with quantitative metrics and pathologist evaluations on cardiac tissue showed that the virtually stained polarization and brightfield images highlight amyloid patterns in a consistent manner, mitigating challenges due to variations in chemical staining quality and manual imaging processes in the clinical workflow.

A supramolecular histochemical system for staining, the system comprising chaotropic ions and a chaotropic ion complexing agent that accepts chaotropic ions as a molecular subject as a molecular guest. The chaotropic ions facilitate diffusion of probes (e.g., antibodies) into and within the tissue sample, followed by binding or dilution of the guest to the subject to facilitate binding of the antibodies to the target antigen and immunostaining or generation of histochemical signals. Alternatively, the micromolecular fluorescent probe can be used as a molecular guest to be compounded with the supramolecular subject to promote deep penetration of the supramolecular subject. A method for performing histology employs a supramolecular system with deep homogeneous histochemistry. The method is relatively fast, scalable, automated and cost effective.

The invention relates to the technical field of biological medicines, and particularly discloses a transcription factor HOMEZ phosphorylation site specific antibody as well as a preparation method and application thereof. The specific antibody provided by the invention can specifically recognize phosphorylation of the 451st site threonine of HOMEZ in a tumor specimen, so that the prognosis condition of the tumor is judged, and a potential action target is provided for clinical diagnosis and treatment of the tumor; moreover, the specific antibody disclosed by the invention can be used for detecting the expression difference between normal cells and tumor cells in a Western blot experiment, and is beneficial to research on the effect of phosphorylation modification of HOMEZ protein in the occurrence and development process of tumor diseases; and the kit can also be used for detecting the phosphorylation level of the HOMEZ protein in a clinical specimen through experiments such as immunofluorescence and immunohistochemical staining, and has a wide clinical application prospect in the aspects of disease diagnosis, treatment, prognosis judgment and the like.

The invention discloses a fluorescence coding probe and a single cell immunoblotting method. The nucleic acid tag comprises oligonucleotide chains f1, f2... fn, n is greater than 2, each oligonucleotide chain contains a fluorophore and a quenching group, partial sequences of the next oligonucleotide chain and the previous oligonucleotide chain are complementarily paired, and the quenching group of the next oligonucleotide chain quenches the fluorophore of the previous oligonucleotide chain. Also disclosed is a quenching tag comprising a complementary strand capable of complementary pairing with an oligonucleotide strand in a nucleic acid tag. The invention discloses a fluorescent coding probe comprising a nucleic acid label, a preparation method of the fluorescent coding probe and application of the fluorescent coding probe in a multi-target single-cell immunoblotting technology, an immunofluorescence technology and an immunohistochemical staining technology. According to the fluorescence-coded multi-target single-cell immunoblotting method disclosed by the invention, multi-target protein detection can be carried out by utilizing limited fluorescence channels, the signal loss is small, and the expansibility is high.

The present invention relates to the field of medical testing. Specifically, the present invention provides a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer and its application. For the first time, the present invention systematically analyzed the content and spatial distribution map of the microenvironment components of CLDN18.2-positive gastric cancer tissue samples by integrating multiple fluorescent immunohistochemistry detection and whole-slice digital imaging quantitative analysis methods. Through multidimensional evaluation of the tumor microenvironment under the treatment background of CT041, a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer was established for the first time, which enables accurate screening of beneficiary populations and risk stratification before treatment, guides treatment selection, and improves treatment efficacy.

The invention relates to the technical field of medical imaging, in particular to a breast cancer tissue HER2 automatic scoring method and device based on a characteristic curve, and the method comprises the steps: carrying out the reading operation of a full-slice image of immunohistochemical staining; extracting a target region of interest of the full slice image; slicing and screening the target region of interest to obtain a plurality of image slices; calculating a percentage-saturation characteristic curve of each image slice, and extracting characteristic information of the percentage-saturation characteristic curve; based on the feature information of the percentage-saturation feature curve, performing preliminary HER2 scoring on each image slice in combination with a rule base and a logistic regression classification algorithm; and integrating the scoring results of the image slices, and outputting a final HER2 score and a characteristic curve visualization graph. According to the method, the feature curve is combined with the rule base and the logistic regression classification algorithm, so that the objectivity of HER2 scoring is improved, and the problems of subjectivity and low efficiency of manual evaluation are reduced.

Microglial spatial heterogeneity remains a crucial yet poorly studied question in light of potential cell-directed therapies for Alzheimer`s disease (AD). Little is known about the dynamics of spatially distinct microglia states, which are either adjacent or non-associated with the plaque site, and their selective contributions to neurodegeneration in vivo. So far, research has essentially focused on pathology-associated microglia. Here, we combined novel multicolor fluorescence fate mapping, single-cell transcriptional analysis, epigenetic profiling, advanced immunohistochemistry and computational modelling to comprehensively characterize the relation of plaque-associated and non-plaque- associated microglia during neurodegeneration. This approach enabled us to identify and characterize non-plaque-associated microglia as a unique and highly dynamic microglial state in a mouse model of AD. Non-plaque-associated microglia modulate network expansion, quickly adapt to environmental cues and their transition to plaque-associated microglia can be specifically modulated during disease, contrary to their reputation as a passive bystander subpopulation. This description of the dynamics of spatially segregated microglial states and their distinct molecular features may therefore open promising new avenues for state-specific therapeutic interventions during neurodegeneration.

The invention belongs to the technical field of immunohistochemical detection, and discloses a modified composite sealing buffer solution as well as a preparation method and detection application thereof. The modified composite blocking buffer solution comprises a basic buffer system, a composite blocking agent, a nonionic detergent, an endogenous interferent blocking agent and an antibody stabilizer, wherein the basic buffer system provides a stable pH environment and ionic strength; the composite sealing agent firstly occupies a shielding site, and the background is lowered; the nonionic detergent destroys hydrophobic interaction, effectively elute and loosen adsorbed molecules, and promote dissolution of components with relatively strong hydrophobicity; the endogenous interferent blocker can be combined with a receptor firstly, so that non-specific combination of an antibody and the receptor is blocked, and the problem of specific background is solved; the antibody stabilizer can protect the activity of the detection reagent and maintain the stability, and the obtained modified composite sealing buffer solution and the kit thereof have the advantages of multiple cooperative sealing mechanisms, prospective blocking of endogenous interference, improvement of the stability, compatibility and high efficiency of the antibody and the like.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-terminal deoxynucleotidyl transferase (TdT) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody disclosed by the invention can specifically recognize TdT protein naturally expressed in cells and tissues, has the advantages of high specificity, high affinity, high sensitivity and the like when being used for immunoblotting, immunohistochemistry and other immunodetection systems, is beneficial to reducing false positive and false negative rates in pathological diagnosis, improves the accuracy of immunodiagnosis, and has a good application prospect. The method has wide application potential in the field of immunological detection of living biological samples. In addition, the antibody disclosed by the invention has cross-species reaction characteristics on homologous TdT proteins of human, mice and rats, so that the application scene of the antibody is greatly expanded.

The present disclosure provides antibodies, including but not limited to monoclonal antibodies, capable of specifically binding the human PAX8 protein. Also provided are nucleic acids encoding the anti-PAX8 antibodies described herein, as well as expression vectors comprising these nucleic acids, host cells transformed with the expression vectors comprising the nucleic acids encoding the anti-PAX8 antibodies, and methods of making the antibodies. The anti-PAX8 antibodies described herein are useful for immunohistochemical detection of human PAX8 protein in tissue samples.

The invention discloses application of jellyfish and snow rabbits in inhibition of ERK phosphorylation level and MAPK pathway and an evaluation method of the jellyfish and snow rabbits, and relates to the technical field of biological medicines.The method comprises the following steps that 1, a treated jellyfish and snow rabbits breast cancer cell group and a control breast cancer cell group are established; and step 2, respectively dividing the two groups of samples in the step 1 into two parts, fixing one part in paraformaldehyde with the mass concentration of 10%, treating, embedding in paraffin for immunohistochemical analysis, and quickly freezing the other part for transcriptomics analysis and the like. According to the invention, UPLC-MS is adopted to determine the main components of SMM, the influence of SMM on breast cancer (BC) is evaluated through in-vivo experiments, in order to deeply clarify the mechanism, network pharmacology and transcriptomics analysis are integrated, finally, immunohistochemistry (IHC) is adopted to verify and explore the exact breast cancer resisting mechanism of SMM, and a scientific basis is provided for potential clinical application of SMM.

The invention relates to a confining liquid and method for reducing background signals in immunohistochemical detection, and belongs to the technical field of immunodetection, and the confining liquid comprises whey protein and an anionic surfactant. By utilizing the confining liquid provided by the invention, background signals generated on a glass slide can be reduced or even eliminated, and the convenience and accuracy of interpretation of an immunohistochemical detection result are improved.

A system and method of categorizing protein expression in biological cells may include receiving a Whole Slide Image (WSI) of an Immunohistochemistry (IHC) assay of cells, stained with two or more color-specific markers, of two or more respective proteins, and applying a stain separation algorithm on the WSI image, to obtain two or more single¬ channel marker images. Based on the two or more marker images, embodiments may generate an enhanced color image, representing expression of the two or more proteins in the assay, and prompt a user to assign at least one label to at least one respective location in the enhanced color image. Embodiments may then use the at least one label as supervisory information, to train a machine-learning (ML)-based classification model, to classify at least one cell -representative location according to categories of expression of the at least two proteins.

The present disclosure relates to synthetic controls useful, e.g. for immunohistochemistry (IHC), as well as kit and methods of manufacture and use related thereto. In some embodiments, the synthetic controls include a solid antigen / carrier protein gel comprising a purified antigen (e.g. at a known quantity) and a carrier protein such as an albumin protein (e.g. a serum albumin protein), an egg white protein or mixture of egg white proteins, gelatin, or polylysine. In some embodiments, the purified antigen is cross-linked to the carrier protein in the solid antigen / carrier protein gel.

The invention discloses an enzyme-labeled secondary antibody polymer for immunohistochemical staining. The enzyme-labeled secondary antibody polymer is formed by combining a secondary antibody with a polymer backbone, the polymer is labeled with a marker enzyme, the polymer backbone is polymethacrylate-2-hydroxyethyl ester, and the marker enzyme is connected to polymethacrylate-2-hydroxyethyl ester through a coupling agent. The present invention utilizes polymethacrylate-2-hydroxyethyl ester to modify proteins, reduce immunogenicity and antigenicity, and can also weaken the hydrolysis of proteases and increase the solubility of protein molecules. The enzyme-labeled secondary antibody polymer is applied to immunohistochemical staining and has high specificity and sensitivity.

The application relates to the field of immunohistochemical staining, in particular to a DAB buffer and a DAB staining solution kit for DAB color development. The application discloses a DAB buffer for DAB color development, and the main components are hydrogen peroxide, nonylphenol polyoxyethylene ether, magnesium sulfate and trisodium citrate. The metal ions in the DAB buffer can enhance the electron transfer speed between DAB and hydrogen peroxide, and improve the color development sensitivity. The nonylphenol polyoxyethylene ether can stabilize the hydrogen peroxide, so that the hydrogen peroxide can be stored for a longer time and the cost is saved. The application further discloses a DAB staining solution kit, which comprises a blocking agent, a reaction enhancer, an enzyme-labeled polymer IgG, a DAB concentrated solution, a DAB buffer and hematoxylin, and the above-mentioned DAB buffer for DAB color development. The DAB staining solution kit of the application can improve the detection sensitivity of immunohistochemical staining, and can also improve the storage stability of the DAB color development solution and reduce the cost.